Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.

By C. Pagnoux, A. Mahr, M. Hamidou, J. Boffa, M. Ruivard, J. Ducroix, X. Kyndt, F. Lifermann, T. Papo, M. Lambert and 9 more. New England Journal of Medicine, 2008

619 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/e0279c75b493f8240d05d72e777480beb0cdd4e3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Kai-Uwe Eckardt
2. B. Kasiske
3. M. Yates
4. R. Watts
5. J. Holle
6. V. Tesar
7. C. Mukhtyar
8. N. Yalçındağ

Citations in the corpus

• KDIGO Clinical Practice Guideline for Glomerulonephritis (2012, background): “3 mg/kg/wk initially and progressively increased to 25 mg/wk) was compared to azathioprine (2 mg/kg/d) after induction of remission with cyclophosphamide and corticosteroids.(726) The study was not designed to demonstrate the superiority of methotrexate over azathioprine in preventing relapses, but ”
• Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. (2014, unknown): “Renal-limited ANCA-associated vasculitis 3 (5) 2 (4) 5 (4)”
• EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis (2016, methodology): “The WEGENT trial compared methotrexate to azathioprine and recruited 126 participants with AAV (GPA 96 and MPA 30) (109).”
• 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of ANCA-Associated Vasculitis (2021, unknown): “Methotrexate and azathioprine are equally efficacious for remission maintenance (19).”